A case-control analysis of lymphocytic chromosome 9 aberrations in lung cancer

Yong Zhu, Margaret R. Spitz, Sara Strom, Gail E. Tomlinson, Christopher I. Amos, John D. Minna, Xifeng Wu

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Cytogenetic aberrations on chromosome 9 have been reported to be one of the most frequent genetic changes in lung tumorigenesis. Although many of these changes have been detected in lung carcinoma specimens, there is growing evidence showing the concordance between chromosomal alterations in primary lung tumors and peripheral blood lymphocytes (PBLs). We investigated whether spontaneous aberrations on chromosome 9 in PBLs are associated with the presence of lung cancer and with a family history of cancer. A personal interview, to construct a detailed epidemiologic profile including family history of cancer, was conducted on 174 lung cancer cases and 162 matched controls. One hundred metaphases from PBLs of each subject were analyzed for chromosome 9 aberrations using the whole chromosome painting technique. Overall, the mean proportion of individuals with chromosome 9 abnormalities in their PBLs was significantly higher in cases (96.0%) than in controls (60.5%) (p < 0.05). After adjustment by age, gender, ethnicity, family size, and pack-years, there was a 16.63-fold significantly elevated odds ratio (OR) for lung cancer associated with chromosome 9 aberrations. When subjects were categorized by frequencies of the chromosome 9 lesions, we observed significantly increased odds ratios of 11.13 (4.66, 26.58) and 27.45 (11.15, 67.54) for individuals with 1 chromosome 9 aberration and ≥2 chromosome 9 aberrations, respectively. By performing family history analyses, we further observed that control individuals with chromosome 9 aberrations were more likely to report a family history of any cancer (OR = 1.67 [0.84, 3.32]) and lung cancer (OR = 2.49 [0.81, 7.67]). Our findings suggest that chromosome 9 aberrations in PBLs might be considered a marker of lung cancer predisposition and may be associated with familial aggregation of cancer.

Original languageEnglish (US)
Pages (from-to)536-540
Number of pages5
JournalInternational Journal of Cancer
Volume102
Issue number5
DOIs
StatePublished - Dec 10 2002

Fingerprint

Chromosomes, Human, Pair 9
Chromosome Aberrations
Lung Neoplasms
Lymphocytes
Odds Ratio
Neoplasms
Lung
Chromosome Painting
Social Adjustment
Chromosomes, Human, Pair 2
Metaphase
Carcinogenesis
Interviews
Carcinoma

Keywords

  • Chromosome 9
  • Family history of cancer
  • FISH
  • Lung cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A case-control analysis of lymphocytic chromosome 9 aberrations in lung cancer. / Zhu, Yong; Spitz, Margaret R.; Strom, Sara; Tomlinson, Gail E.; Amos, Christopher I.; Minna, John D.; Wu, Xifeng.

In: International Journal of Cancer, Vol. 102, No. 5, 10.12.2002, p. 536-540.

Research output: Contribution to journalArticle

Zhu, Y, Spitz, MR, Strom, S, Tomlinson, GE, Amos, CI, Minna, JD & Wu, X 2002, 'A case-control analysis of lymphocytic chromosome 9 aberrations in lung cancer', International Journal of Cancer, vol. 102, no. 5, pp. 536-540. https://doi.org/10.1002/ijc.10762
Zhu, Yong ; Spitz, Margaret R. ; Strom, Sara ; Tomlinson, Gail E. ; Amos, Christopher I. ; Minna, John D. ; Wu, Xifeng. / A case-control analysis of lymphocytic chromosome 9 aberrations in lung cancer. In: International Journal of Cancer. 2002 ; Vol. 102, No. 5. pp. 536-540.
@article{677813abae794c3ab9490ad71a202197,
title = "A case-control analysis of lymphocytic chromosome 9 aberrations in lung cancer",
abstract = "Cytogenetic aberrations on chromosome 9 have been reported to be one of the most frequent genetic changes in lung tumorigenesis. Although many of these changes have been detected in lung carcinoma specimens, there is growing evidence showing the concordance between chromosomal alterations in primary lung tumors and peripheral blood lymphocytes (PBLs). We investigated whether spontaneous aberrations on chromosome 9 in PBLs are associated with the presence of lung cancer and with a family history of cancer. A personal interview, to construct a detailed epidemiologic profile including family history of cancer, was conducted on 174 lung cancer cases and 162 matched controls. One hundred metaphases from PBLs of each subject were analyzed for chromosome 9 aberrations using the whole chromosome painting technique. Overall, the mean proportion of individuals with chromosome 9 abnormalities in their PBLs was significantly higher in cases (96.0{\%}) than in controls (60.5{\%}) (p < 0.05). After adjustment by age, gender, ethnicity, family size, and pack-years, there was a 16.63-fold significantly elevated odds ratio (OR) for lung cancer associated with chromosome 9 aberrations. When subjects were categorized by frequencies of the chromosome 9 lesions, we observed significantly increased odds ratios of 11.13 (4.66, 26.58) and 27.45 (11.15, 67.54) for individuals with 1 chromosome 9 aberration and ≥2 chromosome 9 aberrations, respectively. By performing family history analyses, we further observed that control individuals with chromosome 9 aberrations were more likely to report a family history of any cancer (OR = 1.67 [0.84, 3.32]) and lung cancer (OR = 2.49 [0.81, 7.67]). Our findings suggest that chromosome 9 aberrations in PBLs might be considered a marker of lung cancer predisposition and may be associated with familial aggregation of cancer.",
keywords = "Chromosome 9, Family history of cancer, FISH, Lung cancer",
author = "Yong Zhu and Spitz, {Margaret R.} and Sara Strom and Tomlinson, {Gail E.} and Amos, {Christopher I.} and Minna, {John D.} and Xifeng Wu",
year = "2002",
month = "12",
day = "10",
doi = "10.1002/ijc.10762",
language = "English (US)",
volume = "102",
pages = "536--540",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - A case-control analysis of lymphocytic chromosome 9 aberrations in lung cancer

AU - Zhu, Yong

AU - Spitz, Margaret R.

AU - Strom, Sara

AU - Tomlinson, Gail E.

AU - Amos, Christopher I.

AU - Minna, John D.

AU - Wu, Xifeng

PY - 2002/12/10

Y1 - 2002/12/10

N2 - Cytogenetic aberrations on chromosome 9 have been reported to be one of the most frequent genetic changes in lung tumorigenesis. Although many of these changes have been detected in lung carcinoma specimens, there is growing evidence showing the concordance between chromosomal alterations in primary lung tumors and peripheral blood lymphocytes (PBLs). We investigated whether spontaneous aberrations on chromosome 9 in PBLs are associated with the presence of lung cancer and with a family history of cancer. A personal interview, to construct a detailed epidemiologic profile including family history of cancer, was conducted on 174 lung cancer cases and 162 matched controls. One hundred metaphases from PBLs of each subject were analyzed for chromosome 9 aberrations using the whole chromosome painting technique. Overall, the mean proportion of individuals with chromosome 9 abnormalities in their PBLs was significantly higher in cases (96.0%) than in controls (60.5%) (p < 0.05). After adjustment by age, gender, ethnicity, family size, and pack-years, there was a 16.63-fold significantly elevated odds ratio (OR) for lung cancer associated with chromosome 9 aberrations. When subjects were categorized by frequencies of the chromosome 9 lesions, we observed significantly increased odds ratios of 11.13 (4.66, 26.58) and 27.45 (11.15, 67.54) for individuals with 1 chromosome 9 aberration and ≥2 chromosome 9 aberrations, respectively. By performing family history analyses, we further observed that control individuals with chromosome 9 aberrations were more likely to report a family history of any cancer (OR = 1.67 [0.84, 3.32]) and lung cancer (OR = 2.49 [0.81, 7.67]). Our findings suggest that chromosome 9 aberrations in PBLs might be considered a marker of lung cancer predisposition and may be associated with familial aggregation of cancer.

AB - Cytogenetic aberrations on chromosome 9 have been reported to be one of the most frequent genetic changes in lung tumorigenesis. Although many of these changes have been detected in lung carcinoma specimens, there is growing evidence showing the concordance between chromosomal alterations in primary lung tumors and peripheral blood lymphocytes (PBLs). We investigated whether spontaneous aberrations on chromosome 9 in PBLs are associated with the presence of lung cancer and with a family history of cancer. A personal interview, to construct a detailed epidemiologic profile including family history of cancer, was conducted on 174 lung cancer cases and 162 matched controls. One hundred metaphases from PBLs of each subject were analyzed for chromosome 9 aberrations using the whole chromosome painting technique. Overall, the mean proportion of individuals with chromosome 9 abnormalities in their PBLs was significantly higher in cases (96.0%) than in controls (60.5%) (p < 0.05). After adjustment by age, gender, ethnicity, family size, and pack-years, there was a 16.63-fold significantly elevated odds ratio (OR) for lung cancer associated with chromosome 9 aberrations. When subjects were categorized by frequencies of the chromosome 9 lesions, we observed significantly increased odds ratios of 11.13 (4.66, 26.58) and 27.45 (11.15, 67.54) for individuals with 1 chromosome 9 aberration and ≥2 chromosome 9 aberrations, respectively. By performing family history analyses, we further observed that control individuals with chromosome 9 aberrations were more likely to report a family history of any cancer (OR = 1.67 [0.84, 3.32]) and lung cancer (OR = 2.49 [0.81, 7.67]). Our findings suggest that chromosome 9 aberrations in PBLs might be considered a marker of lung cancer predisposition and may be associated with familial aggregation of cancer.

KW - Chromosome 9

KW - Family history of cancer

KW - FISH

KW - Lung cancer

UR - http://www.scopus.com/inward/record.url?scp=0037058709&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037058709&partnerID=8YFLogxK

U2 - 10.1002/ijc.10762

DO - 10.1002/ijc.10762

M3 - Article

VL - 102

SP - 536

EP - 540

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 5

ER -